HRIPT Testing for Cosmetic Brands: Study Scope, Reports and Claim Limits
Brands usually start asking about HRIPT testing late in a project, when a retailer questionnaire asks for tolerance data or the marketing team wants "dermatologist tested" or "suitable for sensitive skin" on the carton. At that point the useful question is not "who can run a patch test quickly" but "what will this study actually let us say, about which product, for which users".
This guide is for brand owners, development leads and buyers who commission a human repeat insult patch test through a qualified research provider and then have to decide how the report can be used. It is not medical guidance and not a description of how to run the study. GZ Cosmetics Lab is a manufacturer; we do not operate an HRIPT facility.
Quick answer
- What HRIPT is for: a supervised volunteer study designed to look at irritation and skin sensitisation potential of a product under study conditions.
- Who decides the design: the qualified study provider, with the investigator, safety professionals and ethics oversight. The brand supplies the product, the intended use and the exact claims.
- What the report cannot do: prove that no user will ever react, extend itself to users or uses the panel did not represent, or show efficacy or regulatory approval.
- Where it fits: one possible input to the wider safety file described in our cosmetic safety testing guide. Efficacy claims and general claim briefs are covered in our cosmetic efficacy testing guide.
HRIPT answers one tolerance question, not every patch test question
"Cosmetic patch testing" is a family of studies, not one service. Research providers describe primary irritation, cumulative irritation and HRIPT as separate assessments, alongside ocular and photo-related work. SGS, for example, lists these as distinct study types in an article about research on children's products; we cite it only for the distinction between study purposes, not for its populations or designs. Each study answers a different question, so the first commissioning step is choosing which question you actually have.
| Study type | Question it is designed to answer | What a favourable result does not cover |
|---|---|---|
| Single-application (primary) irritation | Does one exposure under study conditions produce irritation? | Repeated use, or allergic sensitisation |
| Cumulative irritation | Does irritation build up with repeated exposure under study conditions? | Allergic sensitisation, which is a different mechanism |
| HRIPT | Under study conditions, did the product show irritation or signs of induced skin sensitisation in this panel? | Eye-area tolerance, photo-reactions, users outside the panel, or how the product feels in daily use |
| Consumer perception or home-use study | How do intended users perceive the product during real use? | A professionally assessed tolerance result |
If what you really need is how users feel about the product at home, a consumer testing study is the better route. A home-use questionnaire should not be presented as a clinical tolerance study, and an HRIPT should not be presented as proof that users like the product.
We deliberately do not list phase timings, panel sizes, patch quantities or application steps here. Those are protocol decisions for the qualified provider, made for your product, and they are not something a buyer should copy from an article or attempt in-house.
Who decides whether an HRIPT is appropriate
A human study on a cosmetic is a professional decision, not a purchasing default. Whether one is justified depends on the formula, the data already available on its ingredients, the intended users and what the safety assessor still needs. Start with the wider safety assessment rather than treating a human study as the default first step.
The buyer's job is to ask the right questions in writing before accepting a proposal. Useful ones:
- Given the formula and the existing ingredient and safety data, is a human study needed at all, and is HRIPT the right design for our question?
- What safety information does your team, or our safety assessor, need to review before volunteers can use this product?
- Which ethics review applies, how is informed consent obtained, and who is the responsible investigator?
- Who decides panel inclusion and exclusion criteria, and how will those criteria relate to the users named in our claim?
- How will adverse events be handled for participants and summarised for us?
- Which conclusions will the report state, and in what wording?
We have not set out country-specific legal duties for ethics review or consent; ask your provider and adviser what applies where the study is run. One provider, Obelis, describes the choice of patch test design as depending on the product, the target population and the intended claims, and describes HRIPT as concerning irritation and sensitisation under controlled study conditions. Such findings must be read within the study scope, not as a guarantee that nobody will react. That distinction is a useful starting point for the conversation, whoever runs the study. Mentioning a provider here is an example, not a recommendation or a partnership.
Planning tolerance evidence for an ODM launch?
Send the product version, intended users, use and proposed claims. We can discuss the manufacturing and development records within the project scope; any external study and provider must be agreed separately.
The HRIPT decision chain: question, protocol, conclusion, claim
A technically sound HRIPT report can still answer a different question from the claim a brand later wants to make. Four links have to line up.
| Link | Brand fixes before quoting | Provider proposes and justifies | Where it usually breaks |
|---|---|---|---|
| Question | The tolerance question and the exact claim sentence for each market | Whether HRIPT, another study or existing data answers it | The study is chosen before the claim is written |
| Protocol | Product version, intended use site, leave-on or rinse-off, intended users | Design, panel criteria, supervision and how the sample is applied | The relevance of the panel and study exposure to the intended users and use has not been explained |
| Conclusion | What wording the brand hopes to use | The conclusion the data supports, in the provider's own words | A narrow conclusion is summarised internally as "passed" |
| Claim | Final pack, listing and advertising wording | Whether its conclusion supports that wording, with the regulatory adviser | Claim copy goes further than the conclusion |
Three overreadings to avoid
A general panel is not a sensitive-skin, children's or eye-area panel. A study on a general adult volunteer panel describes that panel. It does not automatically support "suitable for sensitive skin", use on children or use around the eyes, and it does not cover every condition of use. Each of those claims names a different population or exposure, and the provider and safety assessor have to say whether the evidence reaches it.
"No reactions observed" is not "zero allergy risk". Read the actual observations and the investigator's interpretation: a favourable overall conclusion is not itself a statement that no event or irritation was recorded. If the report states that no reactions were observed, that statement remains limited to its panel and conditions. A finite panel cannot show that no user anywhere will react, so it does not support "hypoallergenic for everyone", "never causes allergies" or "safe for all skin".
"Dermatologist tested" is not "dermatologist recommended". A test-type claim says a stated kind of test took place under the relevant professional supervision with favourable results. It does not say a dermatologist endorses the product, that it treats any condition or that a regulator has approved it. In the United States, FDA explains that cosmetic products are not approved before marketing; color additives are treated separately. A tolerance report is not an FDA approval.
Illustrative commissioning example: a "sensitive skin" claim
The following is an illustrative commissioning example, not a client project, and it implies no real study outcome.
A brand plans a fragranced leave-on face cream and wants "suitable for sensitive skin" on the carton. The team holds an HRIPT report from an earlier development version. The report describes a general adult panel, and its conclusion is worded for that panel only. The marketing brief assumes the report "covers" the new claim.
The development lead sends the report and the proposed wording to the study provider and the brand's safety assessor, with these questions:
- Product identity. The tested sample was an earlier version with a different fragrance. Does a professional relevance review consider the existing result relevant to the launch formula, or not?
- Population. How did the panel criteria treat people who describe their skin as sensitive? Were they represented in a defined way, or not specifically addressed?
- Conclusion. Does the report's conclusion say anything about a sensitive-skin sub-group, or only about the panel as a whole?
- Use conditions. How do study exposure conditions relate to daily use of a leave-on face product, in the provider's professional view?
- Claim wording. What, if anything, does the current evidence support, and what further evidence would a "sensitive skin" claim need?
Until those answers are in writing, the claim stays unapproved. The reason is not that the earlier study was poor. It answered a different question: a different formula version, a population not defined around sensitive skin, and a conclusion that does not mention the claimed user group. The evidence still missing is a relevance decision on the formula change and evidence that actually reaches the named users.
The brand's realistic options are to hold the claim, to use only wording the provider and regulatory adviser agree the evidence supports, or to ask the provider whether a study designed around the claimed users is appropriate. Changing a word or two does not by itself make a claim compliant; the wording still has to be checked against each market's rules.
An HRIPT report check for buyers
Sample identity matters, but it is only the first row. Read the report against the claim, and leave medical and statistical interpretation to the professionals who wrote it.
| Report element | What the buyer checks | Who interprets it |
|---|---|---|
| Sample identity | Formula version, batch and fragrance match the product being launched, or the difference is recorded | Brand and manufacturer confirm; provider records |
| Study objective and population | The stated objective and panel description match the users named or implied in the claim | Provider explains; safety assessor judges relevance |
| Supervision and protocol responsibility | The responsible investigator, protocol reference, ethics review and consent process are identified | Provider |
| Participant flow and adverse events | The report shows how many enrolled, completed and withdrew, with withdrawal reasons and adverse events summarised without personal data | Provider presents; safety assessor reviews |
| Observations and interpretation | Recorded observations are shown separately from the professional conclusion drawn from them | Investigator or qualified professional |
| Scope limits | The report states which users, uses and conditions it does not cover | Provider |
| Proposed claim | Every word of the intended claim is supported by the stated conclusion, not by the summary sheet | Regulatory adviser with the safety assessor |
If a row cannot be answered from the report, ask the provider before the claim goes to artwork. Do not draw your own medical conclusion from the raw observations, and do not request participants' personal data; it stays with the provider.
When the formula, fragrance or use changes
An HRIPT report describes the version that was tested. A fragrance swap, a new preservative, a higher level of an active, a different raw material grade, or a move from body use to face or eye-area use can all change whether the report is still relevant.
That does not mean every change requires a complete repeat study, and it does not mean the original report can simply be reused. Ask the provider and the safety assessor for a documented relevance review: what changed, whether it could affect tolerance, and whether the existing evidence, a bridging justification or new work is appropriate. File the decision with the change record so the claim file and the product stay aligned.
Is HRIPT mandatory, and what does it cost?
There is no universal answer. Whether a human tolerance study is expected depends on the market, the product, its users, its claims and the judgement of the safety professionals involved.
For the United States, FDA's MoCRA page says the responsible person must keep records supporting adequate safety substantiation, and that neither the law nor FDA regulations require specific safety tests for individual products or ingredients. That statement is about the US only. It does not tell you what other markets expect, and it is not a reason to skip a study your safety assessor considers necessary. For an EU launch, have the evidence reviewed by your EU safety assessor and Responsible Person.
Cost and timing depend on the provider's assessment of the product, the design and the population. A fixed price or duration quoted before anyone has seen the formula and the claim is a reason to ask what has been assumed.
Preparing tolerance evidence on an ODM project
Resolve tolerance questions while the formula, fragrance and claims can still be reviewed, rather than treating them as paperwork after artwork is fixed. On an ODM development project, our part is the product side of the evidence: supplying defined formula versions and batches for any study, keeping the formula and batch records a report needs to link to, and flagging formula or fragrance changes that may affect existing evidence.
To scope tolerance evidence with us, bring:
- The product type and the formula or sample version you want to use
- Intended use: site, leave-on or rinse-off, frequency
- Target users and target markets
- The exact claims you want, including any test-type wording
- Any existing tolerance or safety reports, with the version they relate to
Where an external tolerance study is needed, the provider, scope and cost range are confirmed per project in writing. We do not promise a particular study provider, a fixed price or a study result. When the product and claims are clear, send your development brief for a quote.
Frequently asked questions
Is HRIPT the same as a cosmetic patch test?
HRIPT is one type of cosmetic patch testing. Single-application and cumulative irritation studies are also patch studies, but they answer narrower irritation questions and do not address sensitisation in the same way.
Does an HRIPT make a product hypoallergenic?
No study can show that nobody will react. Whether any tolerance-related claim can be made depends on the study's stated conclusion and the rules in each market, so confirm the wording with your regulatory adviser.
Can our team test the product on staff instead?
Informal skin tests by staff or customers are not a substitute for a professionally supervised study with ethics oversight and informed consent, and they should not be described as one.
Does GZ Cosmetics Lab run HRIPT studies?
No. We are a manufacturer. We prepare documented samples and records; any external study is scoped with a suitable provider and confirmed per project.
Ready to Start Your Project?
Tell us your product requirements. Within 24 hours, our technical team will reply with a quotation or the questions needed to prepare one.